Similar articles

• Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.

  Balogh A, Merkel U, Looks A, Vollandt R, Wollina U. Balogh A, et al. Exp Toxicol Pathol. 1998 Sep;50(4-6):397-401. doi: 10.1016/S0940-2993(98)80025-0. Exp Toxicol Pathol. 1998. PMID: 9784014 Clinical Trial.
• Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.

  Heald PW, Perez MI, Christensen I, Dobbs N, McKiernan G, Edelson R. Heald PW, et al. Yale J Biol Med. 1989 Nov-Dec;62(6):629-38. Yale J Biol Med. 1989. PMID: 2534648 Free PMC article.
• [Documented effect of extra corporeal photopheresis on T-cell mediated diseases].

  Kofoed K, Schiødt I, Gniadecki R. Kofoed K, et al. Ugeskr Laeger. 2011 Jun 27;173(26):1869-74. Ugeskr Laeger. 2011. PMID: 21712008 Review. Danish.
• Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis.

  Balogh A, Merkel U, Looks A, Vollandt R, Wollina U. Balogh A, et al. Skin Pharmacol Appl Skin Physiol. 1998;11(4-5):258-65. doi: 10.1159/000029835. Skin Pharmacol Appl Skin Physiol. 1998. PMID: 9885410 Clinical Trial.
• ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.

  Geskin L. Geskin L. Skin Therapy Lett. 2007 Jun;12(5):1-4. Skin Therapy Lett. 2007. PMID: 17609808 Review.